← 返回

肿瘤免疫治疗:过去、现在与未来

英文原题:Tumor immunotherapy: past, present, and future.

查看英文原题

Tumor immunotherapy: past, present, and future.

PubMed 2025/07/14(内容时间) Int J Surg Q1 · IF 9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

Jenner和Pasteur的开创性贡献标志着该领域的范式转变,将免疫学从神秘经验的领域转变为可重复科学的领域。这一转变的基本原理,即利用病原体特征来激发特异性机体防御,至今仍是当代免疫治疗的基本原理。在本综述中,我们从免疫治疗的起源和发展出发,提出了肿瘤免疫的“协同功能环路”模型,该模型包括抗原感知环路、细胞毒性杀伤环路、免疫调节环路和肿瘤教育环路。这些环路之间的动态平衡对于决定最终的抗肿瘤效果至关重要。

我们提出了肿瘤免疫治疗的分级疗效金字塔,依据免疫反应的生物学深度进行划分,包括三个层次:局部微环境重塑、全身免疫激活和精准细胞杀伤。

我们系统比较了各种免疫治疗技术的疗效、安全性、个体化程度、工程化潜力和联合治疗潜力。本分析借鉴了成功和失败的临床试验,为免疫治疗的格局提供了全面而细致的视角。对成功临床试验的回顾表明,有效的免疫治疗必须考虑多个因素,包括肿瘤类型、分子标志物表达、免疫微环境、患者的免疫状态和治疗史。相反,临床试验的失败凸显了重大挑战,包括机制的复杂性、肿瘤异质性、免疫抑制与免疫逃逸以及耐药性。本文阐述了当前面临的挑战,并提出了解决这些问题的新视角。

展开英文摘要原文

The seminal contributions of Jenner and Pasteur marked a paradigm shift in the field, transitioning immunology from the realm of mystical experience to that of reproducible science. The foundational principle underlying this transition, namely the utilization of pathogen characteristics to stimulate specific bodily defences, continues to serve as a foundational principle in contemporary immunotherapy.

In this review, commencing with the origins and development of immunotherapy, we propose a "synergistic functional loop" model of tumor immunity, which comprises an antigen-sensing loop, a cytotoxic-killing loop, an immunoregulatory loop, and a tumor-educating loop. The dynamic equilibrium between these loops is pivotal in determining the ultimate anti-tumor effect.

We propose a hierarchical efficacy pyramid for tumor immunotherapy, delineated by the biological depth of the immune response, which comprises three levels: local microenvironmental remodeling, systemic immune activation, and precise cell killing. A systematic comparison of the efficacy, safety, degree of individualization, engineering potential, and combination therapy potential of various immunotherapeutic techniques is conducted. The present analysis draws from successful and failed clinical trials, offering a comprehensive and nuanced perspective on the landscape of immunotherapy.

A review of successful clinical trials indicates that effective immunotherapy must take into account several factors, including the type of tumor, the expression of molecular markers, the immune microenvironment, the patient's immune status, and treatment history.

Conversely, the failure of clinical trials highlights significant challenges, including the complexity of mechanisms, tumor heterogeneity, immunosuppression and immune escape, and drug resistance. The current challenges are elucidated, and novel perspectives on addressing these issues are proposed.

论文信息

作者
Huang Y、Ge H、Zhang Z、Liu X、Zhong K、Tong A、Li G、Zhou L
单位
Department of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, China.China
文献类型
综述
期刊
International journal of surgery (London, England)2025 Nov 1
原文标识
PubMed 40674222 · DOI 10.1097/JS9.0000000000002919